Serbia is seeking to broaden its technology economy beyond software services and engineering through the BIO4 project, an initiative designed to build a biotechnology ecosystem around research, laboratories, startups and large companies. The project represents a shift toward science-based intellectual property, a model that differs substantially from Serbia’s established technology sector, which has been driven largely by software services, engineering expertise and foreign-owned development centres.
Biotechnology requires longer development periods, greater capital investment and extensive laboratory infrastructure. Companies in the sector also operate within regulatory frameworks and depend on intellectual property as well as patient or biological data.
Research infrastructure and industry links
The planned BIO4 ecosystem is expected to bring together more than 1,000 PhDs and over 300 laboratories, alongside universities, startups and large companies. The commercial potential of the ecosystem will depend on how effectively those participants are connected. Research activity can generate economic value when scientific teams establish companies, license discoveries, secure venture capital and develop research or commercial relationships with pharmaceutical, food, agriculture and diagnostics businesses.
Serbia has several potential areas for biotechnology development. Precision agriculture and food technology could build on the country’s substantial agricultural base, while medical diagnostics and bioinformatics could combine clinical expertise with existing software capabilities.
Environmental biotechnology is another potential area, particularly in applications related to water and waste. The investment does not require Serbia to establish a global pharmaceutical company; a portfolio of specialised businesses holding patents and selling high-value products or research services internationally could provide the basis for the sector.
Capital requirements create a different financing model
Financing represents a significant challenge for biotechnology companies compared with software startups. Software businesses can often reach customers with comparatively limited initial capital, while biotech companies can spend years developing products before generating revenue. Laboratory infrastructure, certification and clinical trials can require substantial cash investment. Serbia therefore needs investors prepared to accept technical risk and longer investment periods, alongside grant mechanisms capable of supporting projects without leaving them permanently in the research phase. Corporate venture partnerships with global life-sciences companies could consequently play a larger role than conventional domestic venture funds in financing biotechnology businesses.
Measuring BIO4 by commercial outcomes
The government’s role is also expected to change as the ecosystem develops. Public capital can be used to establish laboratories and research infrastructure, while the selection of commercially successful companies should remain separate from that role. The performance of BIO4 can instead be assessed through licensing income, spin-outs, private R&D contracts, venture financing rounds and products entering regulated markets, rather than laboratory occupancy or the number of conferences and other events.
The project therefore extends beyond science policy into Serbia’s broader technology and economic development model. Its objective is to determine whether the country’s human capital can be converted into owned intellectual property and internationally marketable biotechnology products and research services.
